EASL Studio Podcast: Hepatitis C, Re-infection or Failure of Treatment in People Engaging in High Risk Practices – Do These Labels Matter in 2025? episode artwork

EPISODE · Sep 25, 2025 · 35 MIN

EASL Studio Podcast: Hepatitis C, Re-infection or Failure of Treatment in People Engaging in High Risk Practices – Do These Labels Matter in 2025?

from EASL Podcasts

What do we call it when someone with high-risk practices becomes viraemic again after treatment? In this episode, experts discuss the challenges of managing Hepatitis C in people who inject drugs (PWID) and other high-risk groups. Topics include SVR confirmation rates, DAA prescribing practices, acute vs. chronic infection, and real-world reinfection data. Are traditional labels still meaningful or do we need new frameworks for 2025?Moderator: Ahmed ElsharkawySpeakers: Ashley Brown, Tatyana Kushner and Sabela LensAll EASL Studio Podcasts are available on EASL Campus.Click here to see all EASL Video Podcasts on Apple Podcasts.

Episode metadata supplied by the publisher feed · Published Sep 25, 2025

Embed this episode

NOW PLAYING

EASL Studio Podcast: Hepatitis C, Re-infection or Failure of Treatment in People Engaging in High Risk Practices – Do These Labels Matter in 2025?

0:00 35:41

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of EASL Podcasts?

This episode is 35 minutes long.

When was this EASL Podcasts episode published?

This episode was published on September 25, 2025.

Can I download this EASL Podcasts episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!